Repertoire diversity and maturation of HIV-1 vaccine-induced B cell responses by Phad, Ganesh Eknath
From the Department of Microbiology, Tumor and Cell Biology 
Karolinska Institutet, Stockholm, Sweden 
 
 
 
 
 
REPERTOIRE DIVERSITY AND 
MATURATION OF HIV-1 VACCINE-
INDUCED B CELL RESPONSES 
 
 
Ganesh Eknath Phad 
 
 
 
 
 
 
 
 
 
 
 
Stockholm 2018  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All previously published papers were reproduced with permission from the publisher. 
Published by Karolinska Institutet. 
Printed by Eprint AB 2018 
© Ganesh Eknath Phad, 2018 
ISBN  978-91-7831-086-9 
 
 
REPERTOIRE DIVERSITY AND MATURATION OF 
HIV-1 VACCINE-INDUCED B CELL RESPONSES  
THESIS FOR DOCTORAL DEGREE (Ph.D.) 
By 
Ganesh Eknath Phad 
Principal Supervisor: 
Professor Gunilla Karlsson Hedestam 
Karolinska Institutet 
Department of Microbiology, Tumor and Cell 
Biology 
 
Co-supervisor(s): 
Associate Professor Mats Persson 
Karolinska Institutet 
Department of Clinical Neuroscience 
 
Assistant Professor Christopher Sundling 
Karolinska Institutet 
Department of Medicine, Solna 
 
Opponent: 
Professor Stephen Quake 
Stanford University 
Department of Bioengineering 
 
 
Examination Board: 
Professor Jan Albert 
Karolinska Institutet 
Department of Microbiology, Tumor and Cell 
Biology 
 
Associate Professor Annelie Tjernlund 
Karolinska Institutet 
Department of Medicine, Solna 
 
Professor Nils Lycke 
University of Gothenburg 
Institute of Biomedicine  
Department of Microbiology and Immunology 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
िप्रय आई आिण बाबांस 
 
 
 
 
 
 

ABSTRACT 
In the work presented in this thesis, I characterized B cell responses in rhesus macaques 
inoculated with HIV-1 envelope glycoprotein (Env)-based vaccines to define genetic and 
functional properties of the elicited antibodies for an improved understanding of Env 
immunogenicity. 
 
In Paper I, we investigated antibody heavy chain V gene segment 
expression in the overall B cell repertoire and in response to vaccination by using 2 
approaches, 454-pyrosequencing and single-cell RT-PCR of bulk and sorted memory B 
cells, respectively. Both methods gave highly concordant results and identified 
differential expression of the Ig gene segments. We further investigated the VH repertoire 
of antigen-specific memory B cells induced by an HIV-1 Env trimer immunogen. We 
found that the antibody response against Env was highly polyclonal consisting of most 
of the expressed VH segments in immunized subject. In Paper II, we isolated and 
comprehensively characterized genetic properties of a panel of vaccine-induced MAbs 
from Env immunized subjects. We demonstrated that the MAbs were genetically diverse 
with no bias in their V gene usage towards the distinct epitope regions they were mapped 
to, consistent with a highly polyclonal response. MAbs targeting two sub-regions, the 
CD4 binding site (CD4bs) and variable region 3 (V3), were neutralizing. The combined 
activity of these MAbs recapitulated the neutralizing activity observed in unfractionated 
plasma samples of the animals from which they were isolated, consistent with that these 
were the predominant specificities elicited. In Paper III, we used Illumina high-
throughput sequencing (HTS) and developed a novel computational tool, IgDiscover, for 
germline Ig V allele identification. Previous work using targeted genomic PCR of 
germline V genes from Chinese rhesus macaques revealed a striking allelic diversity 
between animals and the presence of many novel alleles, highlighting the limitations of 
existing macaque V gene databases. By using IgDiscover to construct individualized Ig 
germline gene databases, we can improve the accuracy of Ab repertoire analyses in 
outbred populations considerably. In Paper IV, we investigated B cell responses induced 
by a new generation, well-ordered Env trimers. We used HTS sequencing to investigate 
how the response evolved over time and whether it disseminated into different immune 
compartments. We developed an IgDiscover extension module, Clonoquery, to trace 
hundreds of B cell clonal lineages targeting distinct sub-regions of Env in the peripheral 
blood, bone marrow, spleen, draining lymph node and gut. We detected broad 
dissemination of Env-specific B cell clones in all compartments measured, except gut. 
We showed that some lineages were greatly expanded and that the mean level of somatic 
hypermutation of the variants within each lineage increased with boosting, replacing 
previous variants from the same lineage in both blood and bone marrow.  
In conclusion, this thesis offers a new information about the genetic and 
functional composition of Env-specific B cell responses in immunized rhesus macaques, 
a highly relevant model for understanding vaccine-induced response in humans. It also 
offers valuable information about the rhesus macaque Ig repertoire in general as well as 
broadly applicable tools for repertoire sequencing. 
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1 VACCINES 
Vaccination is the most successful, powerful, and cost-effective medical measure that 
has saved more lives than any other health interventions existing to date. The world’s 
first vaccine, the smallpox vaccine, was developed in 1796 by the pioneer Edward Jenner. 
His discovery has now led to the eradication of natural smallpox [1]. Almost a century 
after Jenner’s breakthrough, Louis Pasteur introduced the process of attenuation and 
demonstrated its utility by producing a rabies vaccine derived from the killed extracts of 
infected central nervous system [2]. Since then, vaccines have evolved in many different 
types and forms [3-5] and the development continues in the 21st century with new 
strategies and techniques to produce efficacious vaccines that can protect the host against 
various infections, ensuring human longevity and health. At present, several licensed 
vaccines are available for the prevention of bacterial and viral diseases including the 
virus-induced cancers such as cervical cancer caused by human papilloma virus and liver 
cancer caused by hepatitis B virus [6, 7]. Nevertheless, there are several major global 
diseases such as AIDS, tuberculosis, and malaria that are responsible for considerable 
morbidity and mortality worldwide for which no licensed vaccines are available. The 
causative agents for these diseases either possess extensive genetic variability, intricate 
pathogenesis, or have evolved various immune evasion mechanisms, posing major 
challenges to vaccine development [6]. Moreover, most currently licensed vaccines have 
been developed empirically, with limited or no understanding of how they activate the 
immune system against the infection. It is now increasingly appreciated that empirical 
strategies alone are not sufficient for successful vaccine development against current 
pandemics such as those causing AIDS and malaria. 
 
For most of the existing vaccines, antigen (Ag)-specific neutralizing antibodies (Ab) (as 
detected in vitro by ELISA, hemagglutination, or neutralization assays) have been shown 
to confer the protection against infections, and provide the best correlates of protective 
immunity [8]. Nevertheless, cellular immunity comprising of CD4+ T helper (Th) and 
CD8+ T cell responses are also important components of vaccine-induced protection 
against intracellular pathogens [9], especially in the elderly. Although the high specificity 
of antibodies is a key element of protective immunity, it is still largely unknown which 
sub-specificities are responsible for the protection against a given pathogen. Delineating 
the fine Ab specificities of experimental vaccines will provide important clues for 
designing improved immunogens against pathogens that easily escape immune 
recognition such as HIV-1. 
 
Long-term maintenance of pathogen-specific antibody levels is crucial for establishing 
life-long protective immunity and is one of the most important attributes of successful 
vaccines. The durability of immune response can be determined by measuring the half-
life of the polyclonal serum antibody response. The longitudinal maintenance of serum 
antibody responses against several vaccine antigens and infections has been determined 
where Ab half-life was shown to range between 11 years for non-replicating protein 
antigen, such as tetanus, and >3000 years for live attenuated measles virus [10, 11]. 
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However, the mechanism(s) underlying the longevity of serum Ab response is not yet 
clear and remains the subject of debate. Three primary models/theories including, the 
polyclonal stimulation model [12], plasma cell niche competition/displacement model 
[12-14], and imprinted lifespan model of plasma cell longevity [15] have been proposed 
to explain the potential mechanisms contributing the maintenance of long-term protective 
immunity [15]. Multivalent antigens (e.g. measles virus particles) have been suggested 
to induce increased BCR cross-linking and Ag presentation to T follicular helper (TFH) 
cells as compared to monovalent antigens (e.g. tetanus, diphtheria toxoids), resulting in 
genesis of long-lived Ab responses [15, 16]. The persistence of antigen, which is limited 
in case of subunit vaccines compared to natural infection or immunization with 
replicating viral vectors, could be an additional critical factor for the generation of 
durable, high-titer Ab responses and thus, long-lasting immunity.       
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2 B CELLS AND ANTIBODIES 
2.1 A BRIEF OVERVIEW OF B CELL DEVELOPMENT 
B lymphocytes are central in the humoral immune system and they are produced 
continuously throughout life. The development of B cells begins in the fetal liver and 
continues in the bone marrow, differentiating from pluripotent hematopoietic stem cells 
(pHSCs) to immature B cells in a number of distinct steps. During differentiation in the 
bone marrow, stepwise gene rearrangements at the immunoglobulin (Ig) heavy and light 
chain loci in B cells result in the generation of functional B cell receptors (BCRs) [17]. 
In the bone marrow microenvironment, immature B cells expressing functional BCRs 
are subjected to negative selection by self-antigens in a process called central tolerance. 
During this process, B cells expressing self-reactive BCRs undergo either clonal deletion 
or receptor editing or become anergic, whereas B cells with no autoreactivity enters into 
the circulation. Immature B cells with non-self-reactive BCRs after passing this central 
tolerance checkpoint migrate to the spleen, lymph nodes or gut-associated lymphoid 
tissues and continue to differentiate into mature naïve B cells expressing both IgM and 
IgD BCRs. During the maturation, residual B cells expressing autoreactive BCRs are 
eliminated in a process known as peripheral tolerance [18]. B cell passing both central 
and peripheral checkpoints generate the naïve B cell repertoire that is mostly devoid of 
self-reactive clones and capable of recognizing and neutralizing a plethora of non-self-
antigens and pathogens. 
 
 
2.2 ANTIBODY STRUCTURE, GENETICS AND DIVERSITY 
Antibodies are heterodimeric protein complexes consisting of pairs of disulfide-linked 
immunoglobulin heavy (IgH) and light (IgL) chains (Figure 1). Each heavy chain (µ, α, 
ϒ, δ, ε) and light chain (κ, λ) contains functionally distinct variable and constant domains, 
present at the N- and C-terminal regions, respectively, each consisting of approximately 
110-130 amino acids [19]. The variable domains are composed of the complementarity-
determining regions (CDR1-3) as well as the adjacent framework regions (FR1-4), which 
together form a variety of antigen-binding tertiary structures [20]. The variability in the 
variable domains is concentrated in the CDR loops in which the heavy chain CDR3 is 
the most diverse region due to the stochastic recombination and non-templated 
nucleotide additions, while the other CDRs are subjected to variation during the process 
of SHM (Paper IV). Usually, the CDR3 is the principle determinant of antibody 
specificity [21, 22]. However, the CDR1 and CDR2 regions can also contribute 
significantly to antigen binding and in some cases antigen specificity is determined 
predominantly or entirely by the light chains. The framework regions, present as β-
pleated sheets, are less variable and primarily act as scaffolds that support the 
hypervariable CDR loops. The constant regions of the heavy chain (µ, δ, γ3, γ1, α1, γ2, 
γ4, ε, and α2) encode the constant domains, which determine the class and effector 
function of antibody molecules [19]. 
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Figure 1: Schematic of an antibody molecule. The CDR1-3 regions are shown in red and green boxes for heavy 
and light chains, respectively. 
 
2.2.1 The immunoglobulin (Ig) loci  
The immunoglobulin loci encode the many gene segments that recombine to form the 
template for heavy and light chains of Ab molecules. The heavy chain is expressed from 
the IgH locus and the light chain from one of two light chain loci, the lambda (Igλ) or 
kappa (Igκ) locus. Matsuda et al., determined the first full-length physical map of the 
human IgH locus, a 957kb region containing multiple variable (V), diversity (D), and 
joining (J) gene segments located on the distal end of chromosome 14 (14q32.33). DNA 
encompassing the entire IgH locus revealed that it consists of a highly interspersed 
organization of functional and non-functional (pseudogenes) V gene segments belonging 
to seven different families in addition to clusters of D and J germline gene segments [23]. 
Later, the Igκ locus comprising Vκ genes that are organized in two clusters (proximal 
and distal) and Jκ segments, covering 1,820 kb, was mapped to chromosome 2 (2p11.2) 
[24-26], and the Igλ locus consisting of Vλ and Jλ genes was mapped to chromosome 22 
(22q11.2) spanning 1,050 kb [27-29]. In both IgH and Igκ loci, the constant (C) region 
is encoded by separate exon(s) that are located downstream of the J gene segments, while 
for Igλ, there are several C regions interspersed between the J gene segments (reviewed 
in [30]). In rhesus macaques, which are estimated to share ~93% homology to the human 
genome, the overall organization of the Ig loci is similar to those of the human Ig loci, 
but the V, D (heavy only), J and C genes encoding heavy, kappa, and lambda chains are 
located on chromosomes 7, 13 and 10, respectively in macaques [31-33].  
The presence of multiple V, D, and J germline gene segments and their recombination is 
critical to the generation of a diverse Ab repertoire. Despite their importance, our 
understanding of structural and allelic variation in germline genes between individuals is 
far from complete [34, 35]. This is mainly because of the highly complex nature of the 
Ig loci. Genomic analyses of the Ig loci have demonstrated that it comprises multiple 
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repetitive elements and many highly similar genes considered to have evolved via gene 
duplication, divergence [36], and conversion [37]. Due to this complex genomic 
architecture, comprehensive sequencing, assembly and annotation of the Ig loci is 
difficult to achieve [34]. In addition, the Ig loci, specifically IgH, is highly polymorphic 
[23]. A number of early and recent studies using different approaches have shown a 
variety of polymorphisms, including insertion/deletion of VH segments and single 
nucleotide polymorphisms (SNPs) in the IgHV region. The detection of VH 
polymorphisms has resulted in the identification of several polymorphic VH alleles [38-
47], contributing significantly to the VH gene diversity in the population. For humans, a 
number of V gene alleles within the IgH, Igκ, and Igλ loci are cataloged in the 
ImMunoGeneTics (IMGT) database [48-52]. However, the IMGT database significantly 
lacks coverage of the full allelic diversity in the human population. For example, 
sequencing of samples from different ethnic groups revealed a number of population-
specific novel alleles [47, 53]. There is currently growing interest in understanding allelic 
variation across ethnically diverse populations, as this would help to interrogate the 
impact of Ig germline gene polymorphisms on antibody response in infection, 
vaccination, and autoimmune diseases [54]. However, so far, the full nucleotide sequence 
of ~1Mb IgH assembly (V, D, and J gene region except C region) has only been 
determined only twice [23, 55], limiting our knowledge about genetic variation in the Ig 
loci across the population. So far, the size and complexity of the Ig loci have hindered 
genomic sequencing of complete Ig loci from large cohorts of individuals, as it requires 
both longer reads and higher levels of coverage for efficient sequence assembly. In 
addition, Ig alleles obtained from genomic sequencing encompass both functional and 
non-functional/pseudogenic alleles, which are often difficult to distinguish from each 
other, posing an additional challenge for genomic mapping of Ig gene segments [34]. 
While comprehensive genomic sequencing of the full Ig loci remains an obstacle, cDNA-
derived expressed V(D)J sequences are now increasingly seen as a useful resource to 
explore the Ig gene allelic variation among individuals. Novel computational approaches 
and tools have been developed and applied to analyze expressed V(D)J sequences. 
Application of such germline gene inference tools, including IgDiscover (Paper III) and 
TIgGER [56], has led to the identification of several novel V germline gene alleles that 
are not present in current germline database resources. Thorough validation of newly 
identified alleles using these tools is important and include targeted genomic sequencing, 
detection of the same allele in multiple individuals [47, 57] or haplotype inference 
methods [58]. De novo identification of germline alleles from Ab-encoding V(D)J 
transcripts using tools such as IgDiscover enables the construction of personalized 
germline databases without any prior knowledge of an individual’s genetic background. 
The same approach can be applied to create databases of germline alleles for species for 
which complete reference genomes are lacking. Using this approach, we generated 
individualized germline gene databases for a number of rhesus macaques by applying 
IgDiscover, which revealed that the allelic diversity between the animals was extensive 
[59]. Thus, when correctly used, computational approaches can be far more efficient than 
genomic sequencing for studies of antibody germline gene variation at the population 
level. Knowledge of an individual’s germline alleles, or access to a comprehensive 
database of functional germline alleles, is important for studies of B cell responses since 
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it enables correct germline gene assignment and accurate calculation of somatic 
hypermutation [54]. 
 
2.2.1.1 Rearrangement of antibody V(D)J segments 
Rearrangement of the Ab heavy and light chain occurs at different stages of B cell 
development. Recombination of the heavy chain genes takes place before the light chain 
gene assembly begins. The germline sequences encoding each V gene segment of the 
heavy or light chains are comprised of two small upstream exons separated by a short 
intron (Figure 2). An N-terminal signal sequence (or leader sequence) directs the 
translated Ab polypeptide through the rough endoplasmic reticulum which is later 
cleaved from the nascent heavy or light chain in the post-translational processing.  
 
 
 
Figure 2: Schematic of antibody heavy chain and light chain gene rearrangement process (V-(D)-J recombination) 
Leader 1 (L1) and leader 2 (L2) shown in light and brown colors, respectively.  
 
In the genomic configuration of the Ig loci, the V, D, J and C gene segments are present 
as discrete clusters. During B cell development, these V, D, and J gene segments undergo 
somatic gene rearrangement events to form unique variable region exons. Each 
functional V, D, and J gene segment is flanked by recombination signal sequences 
(RSSs). The RSSs consist of highly conserved heptamer and nonamer sequences 
separated by either 12 or 23 base pair (bp) spacers, respectively corresponding to one and 
two turns of the DNA helix and referred as one-turn, or the 12RSS, and two-turn, or the 
23RSS. Effective somatic recombination occurs only between 12RSS and 23RSS 
flanked gene segments. For instance, in the IgH locus each V and J gene segment is 
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flanked by 23RSSs, whereas each D segment is associated with 12RSS. This prevents 
direct V to J joining and allows efficient recombination between, initially the D and J 
segment, followed by joining between the V segment and newly generated D-J product. 
The resultant recombined V(D)J is subsequently spliced to the downstream constant 
region, which typically is the µ-domain, leading to the synthesis of IgM BCRs in 
developing naïve B cells. This stepwise rearrangement process is catalyzed by several 
enzymes, collectively termed the V(D)J recombinase, which are involved in double-
stranded DNA break and repair. During recombination, the ends of the gene segments 
are prone to imprecise exonuclease digestion, and non-germline encoded random bases 
(N bases) are added at the heavy chain VD, DJ, and light chain VJ junctions by the 
terminal deoxynucleotidyl transferase (TdT) to generate the additional diversity at the 
V(D)J junction that encodes the HCDR3 loop. The detailed mechanisms and regulation 
of the V(D)J recombination events have been reviewed elsewhere [19, 60-62]. Following 
the somatic recombination, only productively rearranged heavy and light chains are 
assembled as antibody heterodimers that can either be expressed as membrane-bound 
BCRs or secreted in the form of soluble antibodies [19].  
 
2.2.2 Antibody Diversification 
Prior to exposure to antigen, the generation of a diverse antibody repertoire within a given 
individual occurs early during B cell development in the bone marrow. From 
combinatorial assembly of V, (D), and J segments, junctional diversity generated due to 
imprecision of the recombination process, and combinatorial pairing of IgH and IgL 
chains. Different individuals encode different germline V(D)J alleles and it is also 
becoming increasingly clear that there is significant structural variation in the Ig loci with 
frequent gene segment copy number variation, adding further diversity in the population 
[35]. Additional rare processes such as receptor editing and replacement of V gene 
segment can contribute further mechanisms for antibody repertoire diversity. It is 
estimated that these mechanisms can generate a primary repertoire of  >1011 different 
antibodies [19, 60]. This enormous diversity of the primary naïve B cell repertoire is 
further augmented after antigenic stimulation by two mechanisms - somatic 
hypermutation (SHM) and class-switch recombination (CSR), leading to Ag-dependent 
secondary diversification of the Ab repertoire. Both SHM and CSR increase the efficacy 
of active immune response and are controlled by the activation-induced (cytidine) 
deaminase (AID), an enzyme expressed in the germinal center (GC) B cells. A recent 
study by Shlomchik and coworkers showed that SHM is not only confined to the GC but 
can also occur at extrafollicular sites, leading to affinity matured Ab response against 
Salmonella. Their results suggest that functionally active AID is expressed in non-GC B 
cells during the EF response [63]. 
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2.2.2.1 Somatic Hypermutation (SHM) and Class-Switch Recombination (CSR) 
After immunization or infection, activated mature B cells expressing surface IgM with 
low-to-moderate affinity for their cognate antigen migrate to the GCs in secondary 
lymphoid organs (SLO), where they mutate their rearranged V(D)J sequences via SHM 
as well as alter the C region of the heavy chain via CSR. AID-mediated SHM 
preferentially targets the RGYW or its complement, WRCY (where R=A or G, Y=C or 
T, W=A or T) mutational “hotspot” motifs [64-68]. SHM diversifies the Ab repertoire 
by introducing non-templated point mutations at a rate of 10−5– 10−3/base pair/cell 
division in the Ig genes, generating clonal offspring resulting in antibodies that may 
acquire enhanced binding affinity for a given antigen. The mutations are confined to the 
V(D)J coding region, ~100–200 bp downstream of the transcription initiation site and 
exponentially decaying at the 3’ end, approximately 1.5–2 kb downstream. Thereby, 
SHM is avoided in the critical regulatory elements in the promoter, the intronic enhancer, 
and the constant (C) region genes, the latter which is responsible for the antibody effector 
functions [69, 70]. The CSR, also termed as isotype switching, on the other hand involves 
deletional DNA recombination that occurs between the switch regions to replace the C-
region (Cµ and Cδ) exons with a different set of downstream IgH C-region exons, such 
as Cγ, Cα or Cε. For example, activated naïve B cell can switch from expressing IgM 
and IgD on their surface to expressing IgG, IgE, or IgA. This class switching allows Abs 
to have different effector functions while maintaining the same antigen specificity. 
Although less common, CSR can occur prior to GC formation [71] and also during T 
cell-independent responses, which do not induce GCs [72]. 
 
2.3 ANTIGEN-SPECIFIC B CELL RESPONSES 
2.3.1 B cell Activation and Germinal Center reaction 
Following antigen exposure, mature naïve B cells can recognize and capture their 
cognate antigen in its native form via their BCRs. After priming with the cognate antigen, 
activated Ag-specific B cells internalize, process, and present antigenic peptide 
fragments on major histocompatibility complex (MHC) class II molecules, and begin to 
up-regulate the CCR7 and EBI-2 receptors, which promote the migration of B cells to 
the B cell - T cell borders of the draining lymph node, where they can receive help from 
cognate T helper cells [73-75]. At the B - T cell interface, Ag-primed B cells begin to 
proliferate upon receiving signals from T cells.  After 1-2 days, proliferating B cells 
develop along two pathways; in the first pathway, most B cells with relatively high 
affinity BCRs differentiate into short-lived extrafollicular plasma cells (PC), which 
provide an immediate Ab response to antigen; while in the second pathway, lower-
affinity B cells, in addition to the remainder of the high affinity B cells, enter the GC 
reaction for rounds of SHM and selection, a process in which the cells that acquire 
mutations leading to reduced affinity die [76]. Currently, the mechanisms and signals 
that promote B cell differentiation along these two pathways remain incompletely 
defined. 
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Figure 3: Schematic of proposed model of germinal center (GC) reaction (adapted from [77]). At the B 
cell-T cell border of the SLOs, antigen primed B cells process and presents the antigen to T helper cells 
and competes to receive the co-stimulatory signals (a). The selected B cells are allowed to enter the dark 
zone (DZ) of GC where they proliferate and mutate their cell surface receptors (BCRs) via SHM process 
by up-regulating the components of SHM machinery including AID and the Polη enzyme (b). After one or 
possibly several rounds of proliferation and mutation in the DZ, the B cells migrate to the light zone (LZ) 
of GC where they test their mutated BCRs against the antigen present in the form of immune complexes 
on follicular dendritic cells (FDCs) (c). B cells with very low or no affinity for antigen undergo apoptosis 
due to lack of survival signals, while remaining B cells need to compete for selection signal from limited 
T helper cells (d). B cells with higher affinity will more successfully compete for T cell help and lower 
affinity B cells will undergo apoptosis. After successful interaction with T helper cells, surviving B cells 
have three potential fates: re-entry in to the DZ for further division/mutation, exit the GC as plasma cells 
or exit the GC as memory B cells.  
 
GCs are transient structures that appear within days in the B cell follicles of SLOs in 
response to T cell-dependent antigens. B cells participating in the GC reaction selectively 
up-regulate the transcription factor Bcl-6, which plays critical roles in supporting the 
survival of GC B cells and preventing premature exit from the GC [78]. In addition, 
depending on the expression of CXCR4, GC B cells transit between the dark zone (DZ), 
where they undergo extensive proliferation and SHM, and the light zone (LZ), where 
they are exposed to antigen presented by follicular dendritic cells (FDCs). After several 
rounds of proliferation and SHM, B cells from the DZ migrate to the LZ where they test 
their mutated BCRs for binding to Ag presented on the FDCs. In the LZ, B cells with 
very low affinity BCR will not receive the survival signal and will undergo apoptosis 
[79], whereas the remaining B cells compete for limited T cell help during which the 
high affinity clones outcompete the low affinity clones [80, 81]. Surviving B cells then 
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either re-enter the DZ for further SHM or exit the GC as long-lived Ab-secreting plasma 
cells (LLPC) or as non-secreting memory B cells (MBC) (Figure 3).  
 
2.3.2 Memory B Cells and long-lived plasma cells 
Following the GC reaction, selected high affinity B cells differentiate into quiescent 
MBCs or LLPCs, which together contribute to B cell memory and thus, humoral 
immunity. The signals that determine whether a GC B cell differentiates into MBC or 
LLPC remains poorly understood but asymmetric cell division has been suggested [82, 
83]. 
 
MBCs circulate through the SLOs and the peripheral blood and can also be found in the 
splenic marginal zone [84, 85], mucosal epithelium [86], or near contracting GCs within 
SLOs [87] where they persist for long periods of time in the absence of cognate antigen 
or T cell help [88-90]. Following antigen re-challenge, MBCs proliferate and rapidly 
differentiate into short-lived Ab-secreting cells (ASC) [91, 92], aiding to clear the 
infection, together with the Ab response generated during first encounter with cognate 
antigen arising from LLPCs. While it is still not clear whether MBCs can re-enter the 
GCs upon Ag re-encounter, it has been proposed that IgM+ MBCs can re-gain GC entry 
whereas GC derived IgG+ MBCs differentiate into ASCs [93, 94]. 
  
LLPCs exit from the GC as terminally differentiated ASCs that secrete large amounts of 
high-affinity Ag-specific Abs, providing a first line of defense against recurring 
infections [10, 15, 95]. The majority of the LLPCs are bone marrow (BM) resident where 
they are dependent on survival signals/factors such as APRIL, CXCL12, BAFF and IL-
6 produced by surrounding cells including stromal cells, eosinophils, basophils, and 
megakaryocytes. These cells collectively form the plasma cell survival niche, which is 
responsible for viability of the plasma cells in the BM. The homing of LLPCs to a 
survival niche is dependent on the expression of surface chemokine receptors. For 
example, upregulation of CXCR4 receptor expression leads the migration of LLPCs to 
the bone marrow [96, 97], CCR5 and CCR28 to the mucosa [73], and CXCR3 to sites of 
inflammation [73]. In the BM, survival signals such as APRIL and BAFF mainly act via 
B cell maturation antigen (BCMA) receptor by inducing a critical anti-apoptotic protein, 
Mcl-1, which is essential for survival of BM plasma cells [98]. BM-resident LLPCs are 
maintained independently of memory B cells [99, 100] and can persist for decades in the 
absence of antigen [101, 102]. While LLPCs are believed to be the main source of 
circulating IgG Abs and it has been shown that serum Ab titers derived from LLPCs in 
response to antigens and viruses have a wide range of half-lives (10 to > 3000 years) 
[10]. Recently, Lee and colleagues characterized the BM plasma cells in humans where 
the CD19- CD38hi CD138+ subset, but not the CD19+ CD38hi CD138+ subset was 
identified as LLPCs using morphological, RNA transcriptome, and heavy chain (VH) 
repertoire analyses [103]. However, further studies are required to validate these studies 
using higher resolution methods and functional evaluation of antigen-specific LLPCs. 
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3 ANTIBODY REPERTOIRES 
3.1 ANTIBODY REPERTOIRE AT THE SINGLE CELL LEVEL 
Recent developments in single-cell RT-PCR coupled with Sanger sequencing, cloning 
of Ig genes and expression of recombinant MAbs in mammalian cells allow the 
examination of Abs encoded by up to hundreds of single B cells with distinct 
specificities. The isolation of MAbs is a powerful approach that has improved our 
understanding of humoral immune response in infections [104], vaccinations [105, 106], 
and autoimmune diseases [107, 108] or immunodeficiency syndromes [109, 110] at the 
molecular level. In addition, many MAbs have therapeutic potential and their use 
represent an important strategy for immunotherapy [111]. A plethora of potent broadly 
neutralizing antibodies (bNAbs) against clinical pathogens including HIV-1 [112], 
influenza [113], malaria [114], dengue [115], and Zika [116] have been isolated. Detailed 
characterization of binding epitopes and neutralization mechanisms of some of these 
infection-induced MAbs have revealed sites of vulnerability on pathogens such as HIV-
1 and an increased understanding of the evolution of neutralizing Abs during infection 
[117, 118]. This information has led researchers to design, develop, and test several 
structure-based vaccine candidates in relevant animal models with the aim of eliciting 
similar neutralizing antibody responses [54, 119-121]. Furthermore, the isolation and in-
depth analyses of MAbs elicited by such vaccine candidates have helped to improve our 
understanding of vaccine-induced B cell responses at the genetic, functional [32, 121-
123], and structural level [124]. As shown in this thesis and elsewhere, Sanger 
sequencing of hundreds to thousands of BCRs of vaccine-elicited single B cells have 
revealed the genetic diversity of Ab responses towards specific epitope or antigen (Paper 
I) [125]. In addition, identification of antigen-specific BCR sequences allows tracing of 
individual B cell clones over time, which helps our understanding of how they distribute 
across different immune compartments and how they evolve over time (Paper IV). High-
resolution studies of vaccine-induced antibody responses has important implications for 
the re-design of existing immunogens to improve the elicited responses. 
 
 
3.2 HIGH-THROUGHPUT SEQUENCING (HTS) OF ANTIBODY 
REPERTOIRES 
Single B cell sequencing and cloning methods have provided invaluable information; 
however, they can only characterize 102–103 B cells per experiment. Therefore, using 
this approach alone is unrealistic to capture the astonishing diversity of B cell repertoires 
considering the labor and cost required for such endeavors. In contrast, high-throughput 
DNA sequencing (HTS) of Ab repertoires allow survey of thousands to millions of 
different clones with unique Ab gene rearrangements, providing insight into Ab 
repertoires at an unprecedented level of detail.  
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3.2.1 Experimental considerations  
HTS technologies have developed rapidly over the past decade [126]. However, they are 
still evolving in capacity, capability, and applications and a number of challenges remain 
to unravel their full potential. Compared to Sanger sequencing read length and accuracy, 
common HTS platforms used for Ab repertoire studies produce relatively short reads and 
have higher error rate, which together with potential bias introduced during library 
preparation can skew conclusions drawn from the data. Therefore, sequencing Ab 
repertoires requires careful experimental design, with the major considerations being: 1) 
choice of sequencing platform 2) source and population of B cells 3) choice of template 
(genomic DNA or cDNA), 4) choice of primers in amplifying V(D)J rearrangements, 
gene-specific primer mix (multiplex PCR) versus unbiased methods such as 5’ rapid 
amplification of cDNA ends (5’RACE) and addition of unique molecular identifiers 
(UMI) during cDNA and/or PCR amplification steps and 5) robust computational 
platforms for analysis of the data. 
 
Sequencing platform:  
The most commonly used HTS platforms to interrogate the Ab repertoires are the 
Illumina MiSeq and the Roche 454, each of which offers different advantages and 
disadvantages. The majority of earlier repertoire sequencing studies used the 454 
platform, but in recent years, the development and support to the 454 platform was 
discontinued and eclipsed by a better and more precise l ow cost 
sequencing technology, the Illumina MiSeq platform. Currently, the Illumina MiSeq with 
its improved read length, relatively low error rates, and lower costs per base has become 
a dominant and preferred HTS platform in most of the Ab repertoire investigations [127-
129]. Other platforms such as PacBio and IonTorrent have been used in repertoire 
sequencing [130, 131], but are less optimal due to either lower throughput and/or higher 
sequencing error rate [132].  
 
Source and population of B cells:  
In humans, the most common and easily accessible compartment for B cells is the 
peripheral blood, which used as a primary sample source in many Ab repertoire studies. 
However, studies have estimated that only 2% of total B cells are present in the peripheral 
blood, while remaining B cell diversity distribute between the lymph nodes (28%), the 
spleen and mucosal surfaces (23%), and the red bone marrow (17%) [133]. Therefore, 
sequencing Ab repertoires from peripheral blood does not provide a comprehensive 
picture of B cell diversity in the human body. For ethical reasons, access to tissue 
compartments other than the blood is limited for humans compared to animal models 
such as rhesus macaque or mouse. Rhesus macaques represent an ideal model for Ab 
repertoire studies in compartments that are inaccessible in humans (Paper IV). In 
comparison, mice are different than humans not only in their antibody genetics [134] but 
also in the microanatomy of their tissues [135] and in the definition of their B cell subsets 
[136].  
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Choice of template (genomic DNA or cDNA):  
The DNA template for the construction of libraries for Ab repertoire sequencing can be 
isolated from total lymphocytes, peripheral blood mononuclear cells (PBMCs) or any 
tissue compartment containing B cells. The template may be isolated from a specific B 
cell subset, such as plasmablasts, plasma cells or memory B cells enriched for by flow 
cytometry or magnetic bead separation. Depending on the aim of study, genomic DNA 
(gDNA) or mRNA-derived cDNA can be used as a template to prepare the Ab libraries. 
The use of gDNA allows estimation of the proportion of unique B cell clones in the cell 
populations because of the presence of a single rearranged BCR per cell. Quantification 
of cell abundance is more challenging with mRNA as a template because of non-
uniformity of Ab gene expression in different subsets of B cells. However, an important 
advantage of mRNA as a starting material is that it enables the identification of isotype 
information, which is not possible with gDNA because of the long intron between the J 
gene and constant region [137, 138]. 
 
Multiplex or 5’RACE PCR:  
The amplification of rearranged V(D)J sequences is typically performed with multiplex 
PCR using a mixture of primers targeting the 5’ region of multiple V genes, together with 
an isotype-specific heavy or light chain primer. Alternatively, the 5’RACE approach may 
be used, which enables the amplification of V(D)J sequences with single primer instead 
of primer mix can be used to minimize the potential amplification bias towards specific 
V gene segments [137]. Although the 5’RACE method is thought to result in less biased 
libraries, preferential and biased amplification was observed in TCR sequencing [139], 
possibly due to variable efficiency of the template switching reaction. Also, the 5’RACE 
protocol is generally less efficient than 5’Multiplex [140] and it is limited to RNA as a 
starting material. In addition, 5’RACE is less robust when used on RNA of suboptimal 
quality or limited quantity resulting in high non-specific amplification and short fragment 
contamination from RNA degradation or incomplete cDNA synthesis and template 
switching [141-143]. Furthermore, 5’RACE generates longer PCR products (due to 
amplification of 5’ untranslated regions), which presents a significant challenge to 
current sequencing technology (usually Illumina MiSeq) used in repertoire sequencing. 
An advantages with 5’RACE is that it enables the identification of 5′ untranslated regions 
(UTR) and upstream leader sequences of V alleles, information that can be used when 
designing 5’ multiplex primers for species where the genomic information is limited [59]. 
Prior to PCR amplification, nucleotide barcodes (also called as unique molecular 
identifiers), which are random or semi-random short nucleotide sequences can be 
appended to each mRNA template during RACE or gene-specific cDNA synthesis at 5’ 
or 3’, respectively. Both multiplex PCR and RACE protocols have the potential to affect 
the quantitative aspects of Ab repertoire due to the possibility of heterogeneity in 
amplification efficiency. Therefore, molecular barcoding is essential as it allows accurate 
quantification of the DNA template in the sequencing library and correction of 
sequencing errors (by building consensus of multiple reads having the same barcode), 
enabling error-free immune profiling [137].  
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3.3 BIOINFORMATIC ANALYSIS OF ANTIBODY REPERTOIRE DATA   
High-throughput sequencing of Ab repertoires generates vast amounts of data that 
contain immunological information of enormous complexity. Rigorous analyses of these 
datasets are required to filter and parse the information into interpretable results, but once 
this is achieved the results can greatly improve our understanding of adaptive immunity 
in health and disease [144]. Understanding the formation and dynamics of adaptive 
immune responses during infection, vaccination, malignancy, and autoimmune diseases 
is of particular relevance for the development of novel immunotherapies, vaccine 
candidates and immunodiagnostics. Therefore, there is substantial interest in this field, 
which, in turn, has led to the development of a variety of sophisticated computational 
algorithms and bioinformatic workflows for interrogation of Ab repertoires in humans 
and other species [138, 144]. Ab repertoire analysis is a multistep process and the key 
steps include pre-processing (error correction, read filtering) of sequencing data followed 
by V(D)J germline annotation, and clonotyping/clonal grouping. The output obtained 
from the latter steps can be processed further for secondary quantitative and qualitative 
analyses, such as clonal diversity estimation, selection estimation and analysis of SHM, 
clonal evolution and expansion, and clonal tracing, using numerous methods available 
for such purposes [138]. The wide variety of computational approaches means that there 
are no single standard operating procedure or guidelines, either experimental or 
computational, available for the Ab repertoire analysis. Although it remains a challenge 
to standardize the experimental methods or data processing pipelines due to continually 
evolving sequencing methods and computation tools, considerable efforts are being taken 
by the Adaptive Immune Receptor Repertoire (AIRR) Community to develop minimum 
standards and recommendations for repertoire sequencing studies (http://www.airr-
community. org) [145, 146]. 
 
Preprocessing:  
As discussed above, HTS of Ab repertoires suffer from errors and biases introduced 
during library preparation (PCR artifacts, amplification bias) and during the sequencing 
reaction (platform-specific). Therefore, preprocessing of HTS data is mandatory to 
address these technical issues. The purpose of the preprocessing step is to obtain error-
corrected Ab sequences from raw reads produced by a sequencing instrument. Since the 
biological interpretation of the analysis directly depends on the quality of the data, several 
experimental and computational approaches have been developed and combined together 
to mitigate the impact of errors on the conclusions. The errors and bias in repertoire 
sequence data can be corrected through UMIs, replicate sequencing, sequence clustering, 
quantitative bulk PCR, and via Phred quality score-based filtering [138, 147, 148]. 
 
V(D)J germline gene segment annotation:  
Accurate V(D)J germline gene assignment of error-corrected Ab sequences is critical for 
Ab repertoire analysis depends on how comprehensive and accurate available databases 
are. Several web-based or stand-alone annotation tools of variable efficiency and 
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accuracy such as IMGT [50], IgBLAST [149], iHMMune-align [150], and MIXCR [151] 
that are based on different algorithms, can be used for V, D, and J gene assignments. In 
general, assignment of the V and J gene segments is more reliable than D gene 
assignment because D genes typically are very short and sometime undergo trimming 
during the rearrangement process, which reduces their length further, making accurate 
assignment difficult [152]. The database of human and mouse germline V, D, and J 
sequences accessible through the IMGT repository has been used in almost all published 
Ab repertoire studies so far and as such has been tremendously useful. However, through 
recent HTS work, it has become clear that the allele collection within the IMGT 
repository is incomplete and does not cover the full extent of human genetic variation, 
specifically in V genes [35]. Thus, an important goal is to generate a publicly available, 
comprehensive database of germline V(D)J genes is required for accurate analysis of 
BCR repertoires, an effort that is ongoing in our laboratory in collaboration with the 
AIRR community. In addition, comprehensive germline gene databases for animal 
models frequently used in biomedical research such as rhesus macaques, guinea pig, and 
rabbit do not exist, currently limiting studies of Ab responses in these species. Germline 
gene assignment using any database that is not complete or under-representative of allelic 
diversity in a given species will affect the accuracy of clonal lineage tracing and SHM 
estimations and therefore impact immunological interpretations [54]. The IgDiscover 
tool, developed in paper IV, will be extremely helpful in the endeavor to establish 
accurate and more complete databases of antibody germline genes for humans and 
animals, which in turn will improve the overall of quality of Ab repertoire analysis going 
forward. 
 
Clonotyping (clonal grouping):  
After V(D)J annotations, Ab sequences based on their genetic information can be 
grouped into B cell clones, a process commonly referred to as clonotyping or clonal 
grouping. B cell clones that are descended from a common ancestor usually differ in their 
sequences due to SHM in their Ab-encoding genes, therefore, defining clonal relatedness 
in large sets of mutated Ab sequences is challenging [153]. A common method used 
currently for clonal grouping is to cluster all sequences with the same germline V, J allele 
assignment and CDR3 length along with some level of similarity between their CDR3 
regions. The CDR3 region formed during V(D)J rearrangement is defined for each B cell 
clone and usually remains constant during the affinity maturation process. CDR3 length 
is therefore considered a primary indicator for clonal relatedness. Clonal grouping by 
clustering CDR3s at nucleotide [106, 154] or amino acid level based on 80-100% CDR3 
homology have been performed [148, 155-157]. Different identity thresholds impact the 
clonal grouping differently (paper IV), potentially affecting downstream analyses and 
biological conclusions drawn from them. Currently there are no standard criteria or 
robust definition available for the accurate clonal grouping. 
 
 
 
  16
4 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) 
4.1 HIV-1 STRUCTURE 
The human immunodeficiency virus-1 (HIV-1) is the causative agent of acquired 
immunodeficiency syndrome (AIDS), a global pandemic with over 35 million cases of 
infection and 1.5 million annual deaths worldwide [158]. HIV-1 belongs to the lentivirus 
genus of the Retroviridae family. The members of the Retroviridae family contain two 
positive-sense RNA strands enclosed in a cone-shaped capsid, which in turn is contained 
within the icosahedral structure of the assembled virus particle. Upon budding, the virus 
acquires a lipid envelope derived from the host cell membrane. Upon infection of a new 
target cell, the ~9.2 Kbp long RNA molecules are reverse transcribed into double 
stranded DNA by the extremely error-prone, virally encoded enzyme, reverse 
transcriptase (RT). This process generates the enormous strain diversity of HIV-1 by 
introducing random point mutations in the viral genome. Like other retroviruses, the 
HIV-1 genome encodes three major genes, 5’-gag-pol-env-3’.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Schematic of HIV-1 virus (modified Thomas Splettstoesser, www.scistyle.com) 
 
The gag (group-specific antigen) gene-encoded polyprotein is processed by the viral 
protease to produce the matrix (p17), capsid (p24), nucleocapsid (p7), spacer peptides 
(p1 and p2), and p6 proteins. The pol (polymerase) gene codes for the three viral 
enzymes; protease, reverse transcriptase, and integrase that are essential for the viral life 
cycle. The env (envelope) gene encodes the gp160 envelope glycoprotein precursor, 
which is extensively modified during biosynthesis as described below. The HIV-1 
genome also contains the genes encoding for the accessory proteins (vif, vpr, vpu) and 
the regulatory proteins (tat, rev, nef) (Figure 4) [159, 160]. 
 
4.2 THE ENVELOPE GLYCOPROTEINS 
The envelope glycoprotein (Env) complex, composed of gp120 and gp41, is the only 
virus-encoded determinant present on the HIV-1 surface. As such, it is the sole target for 
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neutralizing antibodies and of great significance for HIV-1 vaccine design. Because HIV-
1 causes a chronic infection and currently circulating strains are the result of years of 
virus evolution in millions of hosts, Env has evolved extensive mechanisms to evade Ab 
responses, including glycan- and conformational shielding. In addition, the native Env 
complex is metastable and dissociates easily, making it an extremely challenging vaccine 
antigen [161]. 
 
4.2.1 Biosynthesis of Env 
In the infected cell, the Env glycoprotein spike is synthesized as a single 90-kDa-
polypeptide precursor consisting of ~847 to 875 amino acids translated from a 4.3kb 
spliced mRNA encoding the env gene [162]. In the rough endoplasmic reticulum (rER), 
this precursor polypeptide undergoes co-translational modification through the addition 
of 25-30 N-linked glycans to the protein backbone, resulting into the formation of a 
glycoprotein with a molecular weight of 160 kDa, termed gp160. The gp160 precursor 
protein assembles into trimers [163-167], which are transported to the Golgi apparatus 
where they are cleaved by host cell-encoded furin protease, generating the mature 
envelope surface glycoprotein, gp120, and the transmembrane glycoprotein, gp41. 
Trafficking through the Golgi apparatus allows processing of the glycans into a mixture 
of high-mannose and complex type N-linked sugars [168]. Following proteolytic 
cleavage, the gp120 and gp41 subunits remain associated through weak, non-covalent 
interactions, expressed as heterodimeric trimer complexes on the surface of infected cells 
[169, 170]. These gp120-gp41 complexes are incorporated into budding virus particles, 
where they are displayed on its surface as a functional trimeric spike. There is, however, 
the possibility that non-functional forms of the envelope spike, such as monomers or 
dimers could also be present on the virus surface as an outcome of either the dissociation 
of non-covalent gp120-gp41 complexes or inefficient processing of the spike during 
biosynthesis.  
 
 
 
Figure 5: Schematic of Env glycoprotein variants after proteolytic cleavage of gp160 precursor polypeptide 
(adapted from ref [171]) 
 
Furthermore, the labile nature of the gp120-gp41 complex leads to shedding of gp120 
from virus particles, generating immunogenic, non-native Env confirmations or ‘decoys’ 
while leaving previously buried determinants in the gp41 ectodomain exposed on the 
viral surface (Figure 5) [172-174]. It was shown that only low levels of functional spikes 
(∼10 spikes/virion) remain embedded in the virus particle making the spike density 
unusually low compared to other viruses [175, 176]. Nevertheless, this is clearly 
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sufficient for the infectivity of the virus given its successful spread in the human 
population. 
 
4.2.2 Structure of Env spike 
During HIV-1 infection, the surface-exposed gp120 subunit of the functional spike 
mediates attachment of the virus to CD4-expressing target cells, whereas gp41 is 
responsible for the fusion of the virus and target cell membranes.  
 
The first glimpse of the HIV-1 Env structure, presented as a crystal structure of a 
monomeric gp120 core in complex with soluble CD4 and the 17b Fab (directed against 
the co-receptor binding site or gp120), was reported by Kwong et al and Wyatt et al in 
1998 [177, 178]. These early structures uncovered the overall architecture of the CD4-
bound form Env. Subsequent to this, several structures of gp120 cores in complex with 
different antibodies and/or ligands [179-189], as well as one structure of gp120 in its 
unliganded form [190]. The overall organization of gp120 in all these structures is highly 
similar, consisting of an inner domain (ID) that faces the trimer axis and gp41, an outer 
domain (OD) that is mostly exposed on the surface of the trimer and is heavily 
glycosylated, and a four-stranded bridging or β-sheet that forms the link between ID and 
OD. The primary receptor-binding site, the CD4bs, is located at the interface between 
ID, OD and bridging sheet (Figure 6).  
 
 
Figure 6: The ribbon diagram of the gp120 core from the 
perspective of the CD4 glycoprotein receptor. Inner domain 
shown in red and thought to interact with the gp41. Outer 
domain, which is variable and heavily glycosylated shown in 
yellow color. The linkage between outer and inner domain is 
bridging sheet shown in blue (adapted from ref [177]) 
 
 
Despite the success in resolving several structures 
of the gp120 core and gp41 subunits, stabilization and crystallization of intact Env spike 
in its native, pre-fusion state remained challenging. For a long time, the non-covalently 
linked metastable conformation of the Env complex, insolubility of membrane-bound 
proteins, extensive and variable glycosylation, and the presence of dynamic domains, 
hindered efforts to determine the molecular structure of the native, trimeric spike 
complex. However, using the SOSIP design (reviewed in [119]) in the context of the 
BG505 strain, a clade A transmitter/founder HIV-1 virus isolated from a Kenyan infant 
[191], well-ordered soluble timers were generated. The SOSIP modifications include i) 
an addition of a disulfide linkage (termed SOS), which allows retention of the natural 
cleavage site between the gp120 and gp41 subunits, ii) an I559P mutation (termed IP) 
that prevents gp41 from “springing”, and iii) the deletion of the membrane-proximal 
external region (MPER) of gp41 to improve homogeneity and solubility of trimeric 
protein. The resulting stable, homogeneous, and non-aggregating protein, referred to as 
  19 
BG505 SOSIP.664 gp140, was found to be recognized by several bNAbs suggesting that 
its structure is close mimic of the native trimer since the epitopes of bNAbs are believed 
to be present only on natively folded trimers [192]. In 2014, Wilson and colleagues 
solved the crystal structure of the BG505 SOSIP.664 trimers in complex with a potent 
bNAb, PGT122 at a resolution of 4.7Å, revealing the prefusion state of gp41, the 
interaction between the gp120 and gp41 protomers, and the spatial arrangement of 
variable regions, V1/V2, V3, HR1 and HR2 domains [193]. In addition, Ward and 
colleagues determined the cryo-electron microscopy (cryo-EM) structure of the same 
Env variant in complex with a different bNAb, PGV04 at a 5.8Å resolution [194]. The 
two structures obtained with different methodologies (X-ray and cryo-EM) were similar 
to each other and consistent with a cryo-EM structure reported by Subramaniam and 
coworkers [195]. More recently, Guenaga et al. reported the high-resolution Env 
structure of subtype C primary isolate 16055 using trimers produced by a different 
strategy than SOSIP design, the native flexibly-linked (NFL) trimers, which are 
described in more  detail in section 4.4.2 [196]. Understanding the structure of the native 
trimeric Env spike for a long time was considered to be a bottleneck for developing an 
effective HIV-1 vaccine, thus these were important improvements.  
 
 
A 
 
B 
 
 
 
 
 
Figure 7: (A) Schematic of a full-length gp160 Env construct of HIV-1 isolate BG505. N-linked glycans 
are numbered on their respective Asn-residues. (B) The modifications in the native gp160 included SOSIP 
mutations and the addition of N332 glycan site (shown in red in B) to produce a stable gp140 trimer, 
referred as BG505 SOSIP.664. (C) Three-dimensional structure (side view) of the BG505 SOSIP trimer. 
The gp120 core is shown in yellow, variable V1/V2 and V3 regions are shown in orange and red, 
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respectively. The gp41 elements are highlighted in green and glycans are represented as grey spheres on 
one of the three protomers of Env. (D) Top view (down to the trimer axis) of Env. Highly variable loops 
V1 to V5 in gp120 mapped to the periphery of the trimer are shown where dashed lines for V2 and V5 
indicate the absence or ambiguous electron density (adapted from [193]).     
 
 
4.3 ANTIBODY RESPONSES TO HIV-1 ENV IN INFECTION 
 
HIV-1 Env is presented to the humoral immune system in several different configurations 
in chronically infected humans, including the infectious native form on the surface of 
virions, shed monomeric gp120, gp120-depleted gp41 stumps on virions and various 
forms of unprocessed forms of gp160 released from the cytoplasm of infected cells [197, 
198]. Following HIV-1 infection, anti-Env Abs are detected within ~1 week of detectable 
viremia [199], primarily against the gp41 ectodomain of Env. Following production of 
circulating anti-gp41 Abs, ~2 weeks later, anti-gp120 Abs that target variable region 3 
(V3) appear. However, these binding Abs are not neutralizing and do not affect viremia 
detectably [199]. Consequently, they exert little or no selective pressure on the Env [200]. 
The first neutralizing Abs (NAbs) against the infecting strain (autologous virus) are 
detectable several months post-infection [201-204]. Although autologous NAbs are not 
effective against the divergent (heterologous) viruses, they can exert significant pressure 
on the circulating virus [205], which promotes neutralization escape by selecting for 
variants that differ by single amino acid substitutions, insertions, deletions or by the 
position of N-linked glycans, shaping the evolution of the virus as the infection 
progresses [206-208].   
 
 
4.3.1 Broadly neutralizing antibodies (bNAbs) 
 
The development of cross-reactive NAbs, also called broadly neutralizing Abs (bNAbs), 
capable of neutralizing a broad range of heterologous HIV-1 variants generally takes 
years of chronic HIV-1 infection [209-212]. Approximately 20-30% of HIV-1 infected 
subjects were shown to develop moderate to highly cross-reactive Abs during the first 
three years of infection [204, 210, 212-216]. Among them, about 1% develop bNAbs 
with exceptionally potent and broad neutralizing activity, which can neutralize diverse 
HIV-1 strains of multiple subtypes. [211, 217, 218]. Recently it was shown that infected 
infants could produce bNAbs 20 months after infection, indicating that genesis of bNAb 
responses is not restricted to the adults [219]. Mapping of broadly neutralizing sera 
revealed a limited set of target epitopes [220-222]. It is generally believed that if a 
vaccine could stimulate bNAbs it would be likely to confer protection against HIV-1 as 
highly potent bNAbs isolated from infected individuals [223, 224] are capable of 
preventing infection in macaques or suppressing viremia in a mouse model of HIV-1 
infection upon passive transfer [225-229].  
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The isolation and understanding of the complex evolution/maturation pathway of these 
bNAbs, along with their molecular interactions with the HIV-1 Env at the atomic level, 
have been possible due to recent technical advancement in single-cell Ab cloning, high-
throughput sequencing, structural biology, and protein engineering [230]. Several of the 
Ab-Ag complex structures resolved to date have revealed important information about 
the conserved surfaces that are present and accessible on the native Env trimer. The 
information about the ‘sites of vulnerability’ or ‘supersites’ such as the CD4-binding site 
(CD4bs), the trimer quaternary and glycan/glycopeptide epitopes on gp120, and the 
membrane-proximal external region on gp41 have implications for immunogen design 
[231-234].  
 
4.4 ENV TRIMER AS A TEMPLATE FOR HIV-1 VACCINE DESIGN 
 
4.4.1 Early generation Env trimers 
An effective prophylactic HIV-1 vaccine must provide protection against the enormous 
variety of circulating HIV-1 strains, and if not sterilizing, must curb the infection before 
the formation of reservoirs. Vaccines developed against HIV-1 to date have shown little 
or no success in more than 200 vaccine trials conducted worldwide [235]. In many of 
these trials, the vaccine antigen was derived from the HIV-1 envelope monomer 
glycoproteins gp120, and/or gp41, however these failed to induce potent and broad 
neutralizing Ab responses against diverse HIV-1 strains [236, 237]. After the failure of 
gp120 monomers as an effective vaccine, the focus of immunogen design shifted towards 
the development of soluble trimeric mimics of the Env spike. The generation of soluble 
Env trimers requires the construct containing both gp120 and gp41 subunits. The 
secreted/soluble proteins are easy to produce and purify with a good yield compared to 
their membrane-anchored counterparts. Thus, one of the early approaches was to 
introduce a stop codon at the C-terminus of the gp41 ectodomain prior to the 
transmembrane domain to allow the truncation of the gp41 subunit, resulting in soluble 
gp140 protein that contain the gp120 subunit and the ectodomain of gp41. However, this 
genetic truncation adversely affected the stability of the already metastable trimer leading 
to misfolding and dissociation of gp140 into the constituent gp120 monomer and trimeric 
gp41ectodomain (reviewed in [238]). This issue was later addressed by either 
inactivating via point mutations or deleting the cleavage site of the gp160 precursor. As 
a result, the association between the gp120 and gp41 subunits was improved, although 
the resultant secreted Env trimers were highly heterogeneous and consisted of a mixture 
of multiple gp140 conformations. The next step in Env engineering involved the addition 
of exogenous trimerization motifs, for example, foldon or GCN4, to the C-terminal of 
gp41 ectodomain, to obtain more stable and homogenous Env trimers. This modification 
improved the recovery of the Env fraction and enabled the production of Env immunogen 
in sufficient amounts to perform immunogenicity studies in animal models [239, 240].  
 
One of this type of soluble Env trimers, gp140 foldon (gp140-F), derived from the clade 
B HIV-1 isolate YU2, was used in papers I and II of this PhD thesis. Soluble YU2 
gp140-F immunogen has been extensively characterized for its antigenic and 
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immunogenic properties in small animals [241-244] as well as in non-human primates 
(NHPs), providing a wealth of important immunological information about the humoral 
immune responses in the context of Env vaccination [32, 122, 124, 245-248]. Although 
this first generation gp140-F trimer was able to induce robust B cell responses in NHPs 
[248] , they failed to elicit the antibodies that were capable of neutralizing a broad panel 
of circulating HIV-1 strains (also called as Tier 2 viruses) ([32], paper I). In recent years, 
following the introduction of new analytical methods to study the molecular 
conformations and biophysical properties of Env trimers, it has become clear that gp140-
F trimers are not faithful mimetics of the native Env spike and that they have an open 
conformation exposing several non-broad neutralizing epitopes [124, 249-254]. While 
the foldon trimers were designed empirically in the absence of a high-resolution crystal 
structure of the native Env spike, they represented a state-of-the art Env design at the 
time, displaying high homogeneity by standard biochemical gel and chromatography 
analysis. The use of these trimers in immunogenicity studies provided important initial 
information about the elicited B cell responses and also helped establishing several 
analytical tools and reagents that are broadly used in the field today [32, 122-125, 248, 
255, 256]. 
 
4.4.2 Next generation native-like Env trimers 
As described in section 4.2.2, the two key substitutions, 1) the introduction of cysteine 
residues in each of the gp120 and gp41 subunits to covalently link gp120 to gp41 (501C-
605C; referred to as SOS) and, 2) the insertion of a helix-disrupting point mutation, 
I559P, in heptad repeat 1 to prevent post-fusion conformational changes, formed the 
basis for one of the new generation Env trimers. Additional modification by truncating 
the MPER of the gp41resulted in a soluble, cleaved, well-ordered trimer called 
BG505.SOSIP.664. However, the SOSIP modifications when applied to Env from 
different HIV-1 strains resulted in a mixture of native-like and non-native like forms 
(reviewed in [119]), indicating that Env from the BG505 had an intrinsic ability to fold 
into native-like trimers, unlike other strains.  
 
In the meantime, an alternative approach developed by Wyatt and co-workers involved 
the replacement of the furin cleavage motif REKR with a flexible glycine-serine based 
(G4S) linker at the interface of the gp120 and gp41 subunits to covalently link these two 
subunits together. This design also included the introduction of the I559P point mutation, 
resulting in soluble, cleavage-independent homogenous mimics of the native Env trimer, 
the NFL trimers [249]. The NFL design when applied to the BG505 Env formed well-
ordered trimers resulting in homogenous trimer preparations, while Env from strains such 
as JRFL (clade B) and 16055 (clade C) produced a mixture of well-ordered and non-
well-ordered trimers, aggregates, dimers and monomers. This demonstrated that BG505 
Env is an exception in its ability to form a high percentage of native-like trimers by either 
the SOSIP or NFL modifications. To obtain well-ordered trimers from a non-
homogenous complex mixture, positive selection using trimer-specific bNAbs such as 
PGT145 or VRC26, or negative selection to remove disordered trimers by a non-bNAb 
such as the CD4bs-directed MAb, F105 were used, however, the percentage recovery of 
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well-ordered trimers was low [249, 250]. To increase the yield of well-ordered trimers 
more sophisticated approaches, such as structure-guided enhancements, were applied to 
the initial NFL trimer design. Using BG505 structural information, 8 or 15 amino acid 
residues near the gp120-gp41 interface that are involved in trimer stability, referred as 
trimer-derived (TD), were identified and transferred to the 16055 or JRFL Envs, 
respectively. The resultant trimer is termed as 16055 NFL TD or JRFL NFL TD. Further 
optimizations were made, including introduction of a cysteine residue pair (I201C-
A433C) to prevent CD4-induced conformational changes after gp120:CD4 interaction 
(trimers referred as NFL TD CC). Furthermore, glycine substitutions in the gp41 region 
were introduced to obstruct conformational transitions to post-fusion, helix-dominated 
conformations (trimers referred as NFL TD CC (T569G)). These modifications increased 
the overall stability and homogeneity of the trimers and resulted in higher yields [196, 
257]. Recently, Wyatt, Wilson and collaborators solved the crystal structure of the NFL 
BG505 Env trimers, in complex with two potent bNAbs (PGV19 and PGT122), at 3.39 Å 
resolution. These studies demonstrated that the NFL and SOSIP designs are highly 
similar at the structural level and in their glycosylation profiles. In addition, the flexible 
linker that connect gp120 and gp41 units in NFL trimers was found to maintain native-
like prefusion compact structure without distorting known epitopes on Env or affecting 
the inter-domain flexibility, similar to SOSIP constructs [258].  
 
The highly stable, well-ordered NFL or SOSIP trimers enable the use of additional 
modifications such as targeted deletion of N-linked glycans proximal to the conserved 
CD4bs to increase exposure of this principle neutralizing epitope for BCR access and B 
cell activation, without altering other determinants of the well-ordered trimers [259, 260]. 
Such glycan-deleted trimer variants on the 16055 Env background were shown to prime 
the neutralizing Ab responses, efficiently in rabbit immunogenicity experiments [259]. 
In addition, soluble native-like Env trimers or glycan deleted variants can also be arrayed 
on particles to generate virus-like particles (VLPs) [261] or on synthetic liposomal 
nanoparticles to improve immune response by activating more B cells. For example, Env 
trimer-conjugated liposomes were superior in activating Env-specific murine B cells ex 
vivo and more efficient in inducing GC B cells in vivo, compared to soluble Env trimers 
[262]. In NHPs, trimer-arrayed liposomes were also shown to induce superior GC 
responses as well as to generate higher neutralizing Ab titers against the autologous tier 
2 16055 virus compared to the same quantity of strain-matching soluble trimers in 
adjuvant [121]. So far, the native-like Env trimers were shown to induce strong 
neutralizing Ab titers against the autologous tier 2 viruses in the relevant animal models; 
however, potent heterologous neutralization against a broad spectrum of circulating HIV-
1 strains is yet to be achieved.  
 
4.5 ANALYSIS OF ENV TRIMER VACCINE-INDUCED B CELL RESPONSES  
The success of a vaccine relies on the ability to induce robust, long-term protective 
adaptive immune responses. These responses comprise memory B cells, T cells and long-
lasting Ab-producing cells, which differ in terms of their quantity, quality, homing 
properties, and persistence over time depending on the vaccine formulation (antigen, 
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adjuvant, delivery system). An in-depth understanding of B cells responses, the main 
contributor of protective adaptive immunity, is essential for the development of effective 
vaccines against a specific pathogen such as HIV-1. In recent years, a rapid development 
and expansion of analytical tools have enabled higher resolution interrogation of 
pathogen-specific B cell responses after infection or vaccination. Nevertheless, the 
comprehensive analysis of vaccine-elicited B cell responses in humans is difficult due to 
the inaccessibility of tissues including bone marrow, gut, and spleen where key B 
lymphocytes population such as LLPCs resides. However, this is possible in NHPs that 
are used frequently in biomedical research to model human immunology owing their 
similarity to humans both at the genetic and cellular level. Immunogenicity studies using 
early generation Env trimer in NHPs have enabled us to dissect the B cell responses at 
the cellular, functional, and genetic level in different compartments, providing highly 
detailed information about induced B cell responses ([32, 121, 248], paper I, III, IV). 
  
4.5.1 At the cell subset level  
Our group previously showed that inoculation of Env administered in adjuvant elicits 
robust peripheral Env-specific IgG plasma cell and memory cell responses in rhesus 
macaques [248]. Similar response kinetics were observed for another recombinant 
glycoprotein, the influenza virus hemagglutinin (HA) [245]. In more recent 
immunogenicity trials we found that, while the kinetics of induction and contraction 
followed the same pattern as observed with the first generation trimers, the overall 
magnitude of the response was lower upon vaccination with new generation native-like 
Env trimers ([121] and paper IV). The qualitative difference between B cell responses 
in these two studies was likely due to the Env trimers used for vaccination, wherein new 
generation native-like Env trimers are more tightly packed and do not expose non-
neutralizing or non-broadly neutralizing determinants, resulting in a lower overall 
magnitude of induced Ab response [121, 248]. The majority of the LLPCs are bone 
marrow (BM) resident, where they can persist for decades in the absence of antigen [101] 
and are responsible for the production and the maintenance of high-affinity antibodies 
and therefore provide immediate protection upon antigen re-encounter. ELISPOT 
analyses of B cell responses in the BM have shown the different kinetics of Env-specific 
BM plasma cells  ([121, 248] and paper IV).  
 
4.5.2 At the single cell level 
 
While analyses of different subsets of B cells have provided important information about 
the kinetics and magnitude of Env-trimer specific Ab responses, more details about the 
vaccine-induced B cell responses can be obtained by isolating antigen-specific B cells at 
the single cell level. Analysis of Ab responses at the clonal level using single cell RT-
PCR expression cloning enables the examination of the underlying genetic diversity of 
the response and, through the isolation of MAbs, gives opportunities to study functional 
and structural properties of individual antibodies specific for distinct epitopes on the 
antigen (reviewed in [54]). Several years ago, our group established methods to isolate 
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Env trimer-specific MAbs from single memory B cell obtained from immunized rhesus 
macaques. In this thesis, I build on these studies by combining MAb isolation with NGS 
immune repertoire analysis.  
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5 AIMS 
The specific aims of the individual papers were: 
 
Paper I: To determine the antibody VH gene usage in the overall B cell repertoire 
and in response to HIV-1 Env vaccine in rhesus macaques. 
 
Paper II: To investigate antibody responses against HIV-1 Env by isolation and 
evaluation of genetic and functional properties of a panel of monoclonal 
antibodies (MAbs) from immunized rhesus macaques.   
 
Paper III: To develop a program for de novo identification of germline V genes to 
construct individualized V gene databases and to improve the current 
rhesus macaque immunoglobulin germline gene database.  
 
Paper IV: To study the diversity, distribution and maturation of vaccine-induced Env-
specific B cell lineages in the multiple immune compartments of 
immunized macaques.  
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6 SUMMARY OF PAPERS 
A hallmark of the humoral immune system is the diversity of our Ab repertoires that can 
recognize virtually any antigen. For decades, Ab responses to infections or vaccines were 
monitored primarily by serological assays that assess Ab specificities, but which do not 
reveal the underlying dynamics in clonal populations of B cells, or the specific Ig gene 
rearrangements coding for the antibodies. In recent years, the advent of MAb isolation 
methods and high-throughput DNA sequencing has enabled the interrogation of Ab 
repertoires to a higher level of detail, providing greater insight into the molecular details 
of genes encoding thousands to millions of antibodies. In this thesis, I developed and 
used methods to interrogate B cell responses at both genetic and functional level in the 
context of HIV-1 Env vaccination using in a highly relevant animal model for 
understanding human B cell biology, rhesus macaques. We developed a novel 
computational tool called IgDiscover to identify germline Ig alleles (both known and 
previously undefined) present in a given subject, enabling the construction of 
personalized/individualized reference Ig gene databases. The use of IgDiscover to 
produce individualized antibody germline gene databases from outbred populations is 
revealing considerable diversity between subjects, providing new knowledge about the 
immunoglobulin allelic variation in a given species. Importantly, the construction of 
individualized reference databases allows accurate antibody gene assignment, expression 
profiling, SHM estimation and antibody lineage tracing in a given subject. Here, I used 
these methods to comprehensively characterize the genetic diversity, clonal 
distribution/dynamics and maturation of B cell responses induced by HIV-1 Env trimer 
vaccines.  In this section, I briefly present the results of papers I-IV. 
  
6.1 PAPER I:  
Previous work from our group has showed that the germline Ig gene segments encoding 
the Ab heavy and light chains of macaque Abs are highly similar to their human 
counterparts and cluster according to gene family, rather than species, suggesting a high 
degree of conservation in Ig loci [32]. However, detailed knowledge about Ig genetics in 
healthy and vaccinated rhesus macaques was lacking. Thus, in paper I, to gain insight 
into B cell responses at the genetic level, we studied B cell repertoires by using two 
approaches, 454-pyrosequencing and single-cell RT-PCR of bulk and sorted memory B 
cells, respectively. In particular, we investigated the contribution of individual V gene 
segments in total IgG-switched and Ag-specific B cell repertoires from Env-immunized 
rhesus macaques. The mapping of resultant V(D)J sequences to the reference database 
revealed that the overall expression of Ig gene segments in the major VH families (VH1, 
3, and 4) was unequal with few expressed abundantly, whereas others were utilized at 
rare or undetectable frequencies. A similar pattern of gene usage was shown in human 
following 454-pyrosequencing of the human Ab repertoire [263]. Importantly, the 
expression of gene segments detected by both Sanger sequencing and 454-
pyrosequencing methods gave remarkably concordant results despite performing the 
PCR under different condition, indicating that there was no major bias in amplifying 
certain gene segments by the PCR protocols used prior sequencing by either of the 
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methods. In addition, we also investigated the V gene usage in Ag-specific memory B 
cells elicited in response to an experimental protein-based Env vaccine. Specifically, we 
examined >1000 sequences generated from single sorted Env-specific and IgG-switched 
total memory B cells from macaques immunized with well-characterized recombinant 
HIV-1 Env trimers. The memory B cell response to Env was highly polyclonal, 
consisting of diverse Ab-encoding germline V genes, similar to the V gene usage in the 
IgG-switched total memory B cell repertoire. Clonal grouping of a total of 606 Env-
specific sequences estimated that 502 unique Ab clonotypes were present in the Env-
specific memory B cell response, indicating broad diversification of Ag-specific memory 
B cell repertoires upon Env vaccination. The highly polyclonal B cell response we 
observed in our study was similar to that observed following immunization with protein-
based tetanus toxoid in humans, which consisted of ~100 unique Ab clonotype, [264]. In 
contrast to the diverse vaccine-induced B cell response to HIV-1 Env vaccination 
observed in this study, chronic HIV-1 infection was shown to elicit a more restricted 
memory B cell responses consisting of only ~50 clonotypes with a biased usage of 
IGHV1 family gene segments [265], suggesting that skewing of the VH gene usage is a 
consequence of persistent Ag exposure.  
 
6.2 PAPER II:  
In paper II, I extended the genetic analyses of Env-specific memory B cells, studied in 
paper I, to the functional characterization by isolating a panel of vaccine-induced MAbs. 
Specifically, to elucidate which Ab sub-specificities were archived in memory B cells 
elicited by HIV-1 Env trimer vaccination, we cloned and expressed 52 MAbs from single 
sorted Env-specific B cells from two NHP donors. Using differential ELISA with various 
Env ligands I could define distinct sub-determinants of Env the MAbs recognized, 
including the primary receptor binding site (CD4bs), the variable region-1/2 and 3 (V1V2 
and V3), gp41, and the foldon trimerization motif. The germline V, D, and J gene 
segment assignment to Ab heavy and light chains revealed broad gene usage among the 
different Env-specific MAbs, indicating no bias towards the usage of a given gene 
segment against any of the epitopes. The level of somatic hypermutation in V genes of 
most of the MAbs was low. The relatively low levels of SHM we observed in vaccine-
induced MAbs isolated in this study is in contrast to that observed for MAbs isolated 
from HIV-1 infected patients, which are highly mutated, likely as a consequence of 
persistent Ag exposure due to replicating and mutating virus during chronic HIV-1 
infection. Vaccine-induced MAbs are generally less mutated than infection-induced 
MAbs, as shown in paper IV, in our previous study [32], and other studies of vaccination 
[264]. Next, all 52 MAbs were evaluated for their virus neutralizing capacity in the in 
vitro neutralization assay using a panel of commonly used HIV-1 Env pseudoviruses. 
Among all the MAbs, 25% targeting two sub-determinants of Env, CD4bs and V3 region 
were neutralizing and showed distinct neutralization signatures depending on their sub-
specificity, whereas no neutralizing activity was detected for the gp41-, foldon-, or 
V1V2-specific MAbs. The neutralizing activity of the CD4bs- and V3- directed MAbs 
was in agreement with the unfractionated plasma samples, suggesting that they are the 
major specificities archived in the memory B cell pool. Interestingly, while neutralizing 
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activity of the plasma against some viruses was undetected, purified MAbs from the same 
subject showed considerable neutralization against those viruses, indicating the 
importance of MAb isolation to obtain higher resolution analysis of induced B cell 
responses. In summary, isolation and detail characterization of vaccine-induced MAbs 
in this study have provided improved knowledge about the limitations of existing 
immunogens to induce broad protective neutralizing Abs against hypervariable pathogen 
such as HIV-1. We anticipate that in the near future, the systematic analysis as we showed 
here and isolation of additional MAbs elicited by different candidate immunogens and 
immunization protocols will generate informative results that will guide effective vaccine 
discovery efforts against HIV-1. 
 
6.3 PAPER III.  
Comprehensive knowledge of immunoglobulin germline genes is essential to better 
understand the genetic basis of B cell responses. In paper I and paper II, to study the 
genetic properties of primate B cell responses I used our previously annotated and 
published reference germline database [32], which was derived from one female Indian 
rhesus macaque genome. While those studies provided a great deal of baseline 
information about the genetic diversity of Ig genes in Ag-specific B cell responses, the 
total expressed Ab repertoire in rhesus macaques suggested that the existence of 
additional, hitherto undescribed V gene germline sequences, as well as considerable 
variation between individual animals. Thus, we realized that the use of non-human 
primate species for immunoglobulin gene repertoire analyses would benefit greatly from 
the availability of more complete germline V gene databases. To achieve this, we set out 
to devise a method to elucidate individual germline gene repertoires of rhesus macaques 
to facilitate studies of Ab genetics and affinity maturation in outbred populations. In 
paper III, we developed a novel approach combining HTS of expressed IgM repertoire 
with bioinformatic analysis of IgM sequences to identify germline V genes in a given 
subject. The resultant program, called IgDiscover, allows the identification of both 
known and novel germline sequences, enabling the de novo construction of 
individualized reference V gene database. Other computational approaches  to identify 
the novel Ig alleles or detect the Ig polymorphism were reported [56, 266]. However, 
until the development of IgDiscover (paper III), a reliable, rapid and automated method 
to construct subject-specific germline V gene database was not available, especially for 
species that lack a complete reference genome or have incomplete reference sequences 
in regions of high genomic complexity such as the Ig locus. The ability of IgDiscover to 
produce individualized databases with little or no prior genomic information allows both 
inter- and intra-species comparison has broad implications for the field of immunology. 
For example, production of individualized reference databases from Indian- and Chinese-
origin macaques revealed a high degree of allelic diversity in their V genes. The level of 
Ig allelic diversity we observed in macaques was confirmed recently by a study 
comparing Ig alleles obtained from genomic sequencing of the Ig loci from nine 
macaques [33].  Importantly, the availability of definitive reference for each subject 
improves gene assignment and thus, accurate immune profiling and SHM estimations, 
which will accelerate our understanding of V gene usage and selection pressure 
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experienced by particular gene segments during immune reactions.  
 
6.4 PAPER IV. 
In paper IV, I dissect the B cell responses induced by the NFL Env trimers in multiple 
immune compartments and at multiple time points to understand the diversity, the 
distribution/dynamics and the maturation of hundreds of Env-specific lineages. First, 
using IgDiscover we generated an individualized heavy chain germline V gene database 
for the animal selected for detailed investigation. Individualized V gene database is 
necessary for correct genes assignments of Ab sequences, SHM estimations, Ab lineage 
assignments and tracing, as described in section 3.3. We next developed two extension 
modules to the IgDiscover tool, Clonotypes and Clonoquery to interrogate total and Ag-
specific B cell repertoires at the quantitative and qualitative levels, respectively. We 
detected similar V and J gene usage patterns in pre- and post-immunization samples, 
suggesting that Env vaccine-induced response comprise a minor fraction of total memory 
B cell repertoire and consistent with previous knowledge obtained from B cell ELISpot 
analyses [248, 256]. To investigate how individual antigen-specific B cell lineages 
expand and disseminate in different immune compartments, we combined single B cell 
sorting, MAb isolation and high-throughput IgG repertoire sequencing of post-
immunization samples from blood, bone marrow, spleen, draining lymph node, and gut 
(ileum). We sorted over 1000 Env-specific single memory B cells, which comprises over 
200 unique Ab clonotypes based on identical V, J gene usage and identical HCDR3 
region, suggesting highly polyclonal Env-specific response. The Clonoquery based high 
throughput clonal lineage analysis revealed broad dissemination of the vaccine-induced 
B cell clonal linages in blood, draining lymph node, spleen and bone marrow. We 
demonstrated that the level of SHM at the intra-clonal level across different time points 
and sites was different. We found that affinity-matured Ab variants generated in 
response to later boosts replaced or outnumber previous variants from the same lineage 
in both blood and bone marrow. In addition, we detect the large number of variants for 
given B cell clonal lineages in draining lymph node and spleen, which are the sites of 
ongoing GC reaction as we found mixture of Env-specific memory and plasma cells by 
B cell ELISpot analysis. In contrast, in blood and bone marrow, which comprise the final 
output from the GC reaction, using ELISpot assay we detect memory B cells and plasma 
cells, respectively. Furthermore, we analysed the gut (ileum) sample for the presence of 
Env-specific B cells by both B cell clonal lineage tracing and ELISpot analysis. Both 
methods gave highly comparable results with minuscule or no detection of Env-specific 
B cells in the gut (ileum), suggesting that the vaccine response disseminates to this 
compartment poorly. The poor distribution of Ag-specific responses we observed in gut 
is consistent with the minimum clonal overlap that we observed between the IgG 
repertoires from gut and blood or bone marrow and similar to a recent study of total B 
cell repertoires in humans demonstrating that the gut B cell repertoire is qualitatively 
different from the blood B cell repertoire [267]. 
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7 CONCLUDING REMARKS 
The aim of this thesis was to analyse vaccine-induced B cell responses induced by HIV-
1 Env glycoprotein trimer immunization to gain improved understanding of basic B cell 
biology, as well as to guide the design of future candidate vaccines against HIV-1. At the 
beginning of this PhD thesis, very little was known about the Abs elicited by Env 
vaccination in a relevant animal model such as rhesus macaques with no molecular 
understanding of the induced Ab repertoire that these Abs are part of. This was mainly 
due to insufficient information about antibody germline genes in rhesus macaques, 
limiting our knowledge about the genetic makeup of B cell repertoires in this important 
animal model.  
 
The present thesis defines the germline repertoires in rhesus macaques as well as 
comprehensively characterizes the vaccine-induced Ab repertoires in multiple immune 
compartments at high levels of detail. Paper I in this thesis interrogates the total and 
Env-vaccine induced B cell repertoires to comprehend the underlying genetic basis of B 
cell responses. The diverse Env-specific genetic response that we observed was 
comparable to total Ab repertoire, providing a first baseline about the genetic 
composition of vaccine-induced B cell responses against the complex protein antigen. 
The dissection of polyclonal sera at the level of monoclonal antibodies in paper II allows 
characterization and comparison of the fine Ab specificities that are archived in the 
memory B cell pool following Env immunization. The genetic diversity of MAbs 
targeting the same epitope helps to improve our basic understanding of B cell responses. 
Understanding the functional composition by mapping MAbs to their cognate epitopes 
has important implications in designing improved immunogens. Furthermore, the 
IgDiscover tool developed as a part of this thesis in paper III revealed important 
information about allelic diversity in Ig genes in rhesus macaques. The striking Ig allelic 
diversity we observed highlights the necessity of individualized Ab germline database to 
avoid erroneous immunological conclusions drawn from Ab repertoire data and to 
improve the quality of B cell repertoire studies. Importantly, the production of 
individualized germline database opens new avenues to understand Ig allelic diversity in 
human and other species. The resulting information will facilitate the assessment of 
previously unknown associations between immunological profiles, disease susceptibility 
and/or immunization efficiency and efficacy. Finally, dissemination and maturation of 
hundreds of vaccine-induced Ab lineages across multiple immune compartments that I 
studied in paper IV provide a first anatomic atlas of antigen-specific B cell clonal 
lineages elicited in response to Env vaccination. 
 
In conclusion, the highly detailed information about vaccine-induced B cell responses 
against real world antigens such as HIV-1 Env used in this thesis not only updates our 
knowledge of B cell biology in the context of vaccination but also guides to develop 
improved immunization regimens.  
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